MLD according to the WHO classification in AML has no correlation with age and no independent prognosis relevance analyzed in 1766 patients

Klinikum Nürnberg, Medizinische Klinik 5, Hämatologie/Onkologie, Nürnberg, Germany.
Blood (Impact Factor: 10.45). 02/2008; 111(4):1855-61. DOI: 10.1182/blood-2007-08-101162
Source: PubMed


Between February 1996 and December 2004, the German Leukemia Study Initiative registered 1766 consecutive patients for the acute myeloid leukemia (AML) 96 study, all of whom were diagnosed by central cytomorphology according to the French-American-British (FAB) and the new World Health Organization (WHO) classification. We focused our analysis on the prognostic impact of multilineage dysplasia (MLD) as a new parameter of the WHO classification for AML. We could not confirm the WHO statement that MLD occurs most frequently in older individuals, but we confirmed that MLD is often associated with an unfavorable cytogenetic profile (P < .001). In 1332 individuals receiving intensive AML therapy presence of MLD was negatively correlated with complete remission (P = .001) in univariate, but not in multivariate, analysis. Multivariate analysis of either event-free or overall survival again failed to show an independent prognostic significance of MLD besides age, cytogenetics, and, in part, NPM1/FLT3-ITD mutations. Our data support a reassessment of the WHO classification in the light of a more biologic understanding of AML. This study is registered at as #NCT00180115.

Download full-text


Available from: Pascheberg Ulrich,
  • [Show abstract] [Hide abstract]
    ABSTRACT: The principles according to modern views and practical needs of classification of acute leukemia are discussed on the basis of morphological properties of the leukemic cells after panoptic staining and of their cytochemical reactions. This form of classification gives some indications for the choice of treatment and for the prognosis. It is also the permission for the evaluation of therapeutic results, as are the other factors relevant for the prognosis.
    Österreichische Zeitschrift für Erforschung und Bekämpfung der Krebskrankheit 02/1970; 25(1):24-9.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sowohl die akuten Leukämien als auch die chronischen Leukämien sind sehr heterogene Krankheiten, welche sich auf der Grundlage ihrer morphologischen, immunologischen und genetischen Eigenschaften in eine Vielzahl von Subtypen gliedern lassen. Nur eine Kombination verschiedener Methoden der hämatologischen Diagnostik ist in der Lage, diese Subtypen korrekt zu erfassen und dem jeweiligen prognostischen Profil zuzuordnen. Dabei wirken die Zytomorphologie, die Zyto- und Molekulargenetik sowie die Immunphänotypisierung mit der Multiparameter-Durchflusszytometrie zusammen. Moderne Klassifikationssysteme wie die WHO-Klassifikation aus dem Jahre 2001 beziehen all diese Methoden ein, stützen sich aber auch auf bereits länger etablierte, vorwiegend morphologisch begründete Systeme wie die FAB-Klassifikation der akuten myeloischen Leukämie (AML). Angesichts der kontinuierlichen Erweiterung des Spektrums bekannter genetischer Marker und aufgrund tieferer Einsichten in die Leukämogenese werden auch in Zukunft immer wieder Revisionen der gängigen Klassifikationssysteme notwendig sein. Dies kann am Beispiel der AML verdeutlicht werden, bei welcher die Identifizierung der Nucleophosmin-(NPM1-)Mutation bei der Mehrheit der Patienten mit normalem Karyotyp bald eine eigenständige Kategorie für diese Subgruppe erfordern wird. Bei der chronischen lymphatischen Leukämie (CLL) gelingt auf molekularer Basis eine Risikostratifizierung auf der Basis des Mutationsstatus der Gene, welche für die Schwerketten der Immunglobuline kodieren. Somit sind alle Klassifikationssysteme für Leukämien einem ständigen Wandel unterworfen. Diese Übersicht stellt dar, welche Parameter derzeit zur Klassifikation der akuten und chronischen Leukämien relevant sind, welcher diagnostischen Methoden es bedarf, um die notwendigen Informationen bei den jeweiligen Entitäten zu liefern, und welche aktuellen Erkenntnisse richtungweisend für künftige Klassifikationssysteme sind. Acute and chronic leukemias represent heterogeneous disorders which are divided in a variety of subtypes based on morphological, immunologic, and genetic characteristics. A combination of diverse diagnostic methods is necessary to perform a correct classification of these subtypes and to correlate them to the respective prognostic profiles: cytomorphology, cyto- and molecular genetics, and immunophenotyping by multiparameter flow cytometry. Modern classification systems such as the WHO classification (2001) integrate all these methods, although they are based on previous classification systems using preferentially cytomorphological criteria such as the FAB classification of acute myeloid leukemia (AML). However, in consideration of the continuous expansion of the spectrum of known genetic markers and due to deeper insights into the mechanisms of leukemogenesis, these classification systems need to be revised already in the near future. This can be illustrated by the recent detection of the nucleophosmin (NPM1) mutations in the majority of AML patients with a normal karyotype which might soon be followed by an own category for this subgroup within a revised WHO classification. In chronic lymphatic leukemia (CLL) the definition of the molecular mutation status of the genes coding for the immunoglobulin heavy chain by molecular methods was able to improve risk stratification. Thus, all systems for leukemia classification are in continuous change. This review presents a survey of the parameters which are relevant for the classification of the acute and chronic leukemias, of the diagnostic methods which are essential to guarantee the relevant information, and, finally, of recent results of leukemia research which might influence future classification systems.
    Onkopipeline 08/2008; 1(2):41-48. DOI:10.1007/s15035-008-0121-0
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of the study was to assess the contribution of age and disease variables to the outcome of untreated patients with acute myeloid leukemia (AML) receiving varying intensive induction chemotherapy. Patients 16 to 85 years of age with primary AML, known karyotype, and uniform postremission chemotherapy enrolled onto two consecutive trials were eligible and were randomly assigned to induction either with a standard-dose (cytarabine, daunorubicin, and 6-thioguanine) and a high-dose (cytarabine and mitoxantrone) combination, or with two courses of the high-dose combination. Subgroups were defined by karyotype, nucleophosmin and FLT3 mutation, WBC count, serum lactate dehydrogenase, and residual blasts. In 1,284 patients, the overall survival at 4 years in those younger and older than 60 years was 37% versus 16% (P < .001) and the ongoing remission duration was 46% versus 22% (P < .001). Similar age-related differences in outcome were found for all defined subgroups. No difference in outcome according to randomly assigned treatment regimen was observed in any age group or prognostic subset. Regarding prognostic subgroups, molecular factors were also considered. Under harmonized conditions, older and younger patients with AML show modest differences in their risk profiles and equally no dose response to intensified chemotherapy. Their observed fundamental difference in outcome across all subgroups remains unexplained. Further molecular investigation may elucidate the age effect in AML and identify new targets.
    Journal of Clinical Oncology 01/2009; 27(1):61-9. DOI:10.1200/JCO.2007.15.4245 · 18.43 Impact Factor
Show more